Pulse Biosciences

Pulse Biosciences

Pulse Biosciences was founded in 2014 as a medical device company commercializing a proprietary technology called Nano-Pulse Stimulation (NPS). Robert Duggan, who built his fortune as the former CEO of Pharmacyclics before its $21 billion sale to AbbVie in 2015, became Pulse’s chairman in 2018 and CEO in 2020. His involvement deepened sharply after the company shifted its strategy in 2022 to focus exclusively on cardiac applications, centering on a novel system to treat atrial fibrillation via irreversible electroporation—a non-thermal ablation approach developed by a team he backed with significant personal capital. The firm operates as a publicly traded, clinical-stage medical technology company rather than a traditional investment vehicle, but its resource allocation mirrors a family-office concentration bet. Duggan has funded operations through repeated direct purchases of common stock rather than relying on institutional rounds, taking his beneficial ownership above 60% by 2024. The company’s lead program, the CellFX nsPFA 360 Cardiac Catheter, targets the large electrophysiology market by aiming to replace thermal ablation with pulsed-field energy that spares surrounding structures—an approach validated by the first-in-human procedures completed in early 2025. Pulse’s geographic footprint is limited to the US, with R&D and administrative operations consolidated in Miami, Florida after relocating from California in 2024. In September 2024, Pulse Biosciences received FDA 510(k) clearance for its percutaneous electrode system, triggering a move toward a pivotal clinical trial expected to start in 2025. The company maintains a lean structure—public filings show under 100 employees—with Duggan serving simultaneously as chairman, CEO, and primary financier. His philanthropic vehicles, notably the Duggan Family Foundation, are entirely separate legal entities but share a pattern: large, concentrated grants in medicine and education. There are no known co-investor clubs, fund structures, or external wealth-management layers between Duggan and his Pulse position. The structural differentiator is the absence of institutional capital constraints on a clinical-stage public company. Unlike most biotechs that dilute to fund R&D, Pulse’s CEO-controlled treasury approach means pivotal decisions are made by a single economic actor with an indefinite time horizon and no redemption risk. This governance architecture places a premium on Duggan’s engineering judgment and patent strategy, where the company’s 100-plus issued patents form the core asset rather than any diversified portfolio.